Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Mbri-001
2. Npi 2358
3. Npi-2358
4. Npi2358
1. 714272-27-2
2. Npi-2358
3. Plinabulin (npi-2358)
4. Plinabulin(npi-2358)
5. Npi-2358 (plinabulin)
6. Npi 2358
7. (3z,6z)-3-benzylidene-6-[(5-tert-butyl-1h-imidazol-4-yl)methylidene]piperazine-2,5-dione
8. 986fy7f8xr
9. Npi2358
10. (3e,6e)-3-benzylidene-6-[(5-tert-butyl-1h-imidazol-4-yl)methylidene]piperazine-2,5-dione
11. (3z,6z)-3-benzylidene-6-((5-(tert-butyl)-1h-imidazol-4-yl)methylene)piperazine-2,5-dione
12. 2,5-piperazinedione, 3-((5-(1,1-dimethylethyl)-1h-imidazol-4-yl)methylene)-6-(phenylmethylene)-, (3z,6z)-
13. Plinabulin [usan:inn]
14. Plinabulina
15. Plinabuline
16. Plinabulinum
17. Unii-986fy7f8xr
18. Plinabulin [mi]
19. Plinabulin [inn]
20. Plinabulin (usan/inn)
21. Plinabulin [usan]
22. Kpu-2
23. Plinabulin [who-dd]
24. Schembl79095
25. Mls006011262
26. Chembl1096380
27. Ex-a292
28. Chebi:177413
29. Dtxsid201031311
30. Bpi 2358
31. Bpi-2358
32. Zinc3819466
33. Bdbm50030765
34. Mfcd18074510
35. Nsc797934
36. S1176
37. Akos005145762
38. Akos024463284
39. Bcp9000994
40. Ccg-264849
41. Cs-0506
42. Db05992
43. Nsc-797934
44. Ac-32812
45. Hy-14444
46. Smr004703013
47. Bcp0726000116
48. Sw219827-1
49. D09655
50. Brd-k99498722-001-01-8
51. Q15269699
52. (3z,6z)-6-benzylidene-3-((5-(1,1-dimethylethyl)-1h-imidazol-4- Yl)methylidene)piperazine-2,5-dione
| Molecular Weight | 336.4 g/mol |
|---|---|
| Molecular Formula | C19H20N4O2 |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 336.15862589 g/mol |
| Monoisotopic Mass | 336.15862589 g/mol |
| Topological Polar Surface Area | 86.9 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 597 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in cancer/tumors (unspecified).
NPI-2358 is a vascular disrupting agent currently in clinical development for the treatment of cancer by Nereus. NPI-2358 is one of over 200 synthetic analogues that were prepared following the discovery of the compound Halimide isolated from a marine fungus. In preclinical models of cancer, including lung, breast, sarcoma, colon and prostate, NPI-2358 demonstrated potent and selective anti-tumor effects in combination with docetaxel and other oncology therapies, as well as single-agent efficacy in a number of orthotopic models. NPI-2358 interacts with soluble beta-tubulin and prevents the polymerization of tubulin without altering dynamic microtubule function of formed microtubules. As demonstrated in preclinical testing, this target profile results in a highly specific nanomolar cytotoxicity while reducing the side effects seen in first-generation VDAs due to cardiotoxicity, hemodynamic changes and neuropathies.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
84
PharmaCompass offers a list of Plinabulin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Plinabulin manufacturer or Plinabulin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Plinabulin manufacturer or Plinabulin supplier.
PharmaCompass also assists you with knowing the Plinabulin API Price utilized in the formulation of products. Plinabulin API Price is not always fixed or binding as the Plinabulin Price is obtained through a variety of data sources. The Plinabulin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Plinabulin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Plinabulin, including repackagers and relabelers. The FDA regulates Plinabulin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Plinabulin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Plinabulin supplier is an individual or a company that provides Plinabulin active pharmaceutical ingredient (API) or Plinabulin finished formulations upon request. The Plinabulin suppliers may include Plinabulin API manufacturers, exporters, distributors and traders.
Plinabulin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Plinabulin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Plinabulin GMP manufacturer or Plinabulin GMP API supplier for your needs.
A Plinabulin CoA (Certificate of Analysis) is a formal document that attests to Plinabulin's compliance with Plinabulin specifications and serves as a tool for batch-level quality control.
Plinabulin CoA mostly includes findings from lab analyses of a specific batch. For each Plinabulin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Plinabulin may be tested according to a variety of international standards, such as European Pharmacopoeia (Plinabulin EP), Plinabulin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Plinabulin USP).
